Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Ask Vendit Off-Topic Questions -- Ignore unavailable to you. Want to Upgrade?

To: Vendit™ who wrote (2661)	12/15/2004 7:55:43 AM
From: Walkingshadow	Read Replies (1) \| Respond to of 8752

Thanks Reid. Just closed out NURO with a nice profit, arguably a bit too soon. I just love those little jaunts from one rail of the BBs to the other: 139.142.147.218 But... who was it that said it is better to book a profit too early than too late ??? <ggg> Anyhow, I will be replacing that position with something else. Of the stocks from Sunday's list, I don't like the most recent candle in ERTS. It seems like the most extended of the group also. So... I would be leery of that one. The rest look excellent. In terms of timing and how much gas they might have left in their tank, I think I would probably rank the rest of those charts in reverse order: MU NOVL SCH Would you agree? Terry

To: Vendit™ who wrote (2661)	12/15/2004 8:07:02 AM
From: Walkingshadow	Read Replies (1) \| Respond to of 8752

Reid, here's another risky one along the lines of NURO (note the volume!!) that is under my radar, and is coiling up nicely: 139.142.147.218 Some good news in the sector this morning. CHIR just got priority review status by the FDA for Pulminiq. So, for NRMX, today might be their day, and the start of a sweet little trip to the top rail of the BBs maybe? ======================================== Wells Fargo initiates Neurochem (NRMX) with a Buy and $27 target. The co focuses on the development of orally active drugs for neurological disorders and has two late-stage clinical products. Given that Alzhemed (for Alzheimer's disease) addresses a large market with broad, unmet medical needs if approved, it would have blockbuster potential. Currently in Phase III, Alzhemed could become the first in a new class of drugs for AD. While current treatments merely target symptoms of AD, Alzhemed is designed to address the underlying causes by modifying its progression. The firm forecasts Phase III data for Alzhemed in early 2007, a US launch in early 2008, and total peak annual sales of $2 bln. Upcoming milestones for Neurochem include: 1) initiation of a second Phase III trial for Alzhemed in 1Q05; 2) Fibrillex Phase II/III data in 2Q05; 3) NDA filing for Fibrillex in mid-2005; and 4) potential Fibrillex partnership in 1H05. ================================================